All lobbying filings

AVIVA STRATEGIES (FKA MGB CONSULTING)

Lobbying for ENDEAVOR BIOMEDICINES · Biotechnology & therapeutics

Filing · LD-2 quarterly report Q3 report

Reporting period

3rd Quarter 2026

July 1 - Sep 30 · Posted Oct 19, 2026

Income

$51,000

What the client paid this registrant for the period.

Client based in

California

Official filing document

Government bodies contacted 3

Food & Drug Administration (FDA)
HOUSE OF REPRESENTATIVES
SENATE

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 1

Health Issues

FAIR Act HR 7953 FDA Modernization

Bills named in this filing 1

H.R. 7953
FAIR ACT

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.